Omid Vafa

Company: Ancora Biotech

Job title: CBO

Seminars:

TNB-486: An anti-CD19xCD3 T-cell Engager with a Better Therapeutic Window 12:00 pm

TNB-486 is a novel anti-CD19xCD3 bispecific T-cell engager for the treatment of B-NHL Preclinical data shows targeted lysis of CD19+ cells with minimal cytokine release, dose dependent clearance of CD19+ tumor cells in vivo, and favorable pharmacokinetics TNB-486 has a better therapeutic window than first generation TCEs targeting CD19Read more

day: Day Two